Audentes Therapeutics is a biotechnology company focused on developing and commercializing AAV gene therapy products for patients with serious, rare diseases. The company has three lead programs: AT001 for X‑Linked Myotubular Myopathy (XLMTM), AT002 for Pompe disease, and AT003 for the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2‑CPVT). Audentes says its team is experienced and committed to building strong relationships with patient, research, and medical communities. The company closed an oversubscribed $65 million Series C financing to fund its near‑term plans. Proceeds will be used primarily to advance the three lead programs to key clinical milestones and to establish internal GMP manufacturing capabilities. Cowen and Company served as exclusive placement agent for the financing. Audentes Therapeutics is a biotechnology company developing and commercializing gene therapy products for patients with serious, rare diseases. Its two lead programs are AT001 for X‑Linked Myotubular Myopathy (XLMTM) and AT002 for Pompe Disease, both based on AAV gene therapy technology. The company says the new funding will allow it to achieve key clinical development milestones for these programs and to continue research and in‑licensing efforts to expand its pipeline. Audentes completed a $42.5 million Series B financing and previously closed a $30 million Series A in July 2013. The Series B attracted participation from Deerfield Management, Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures, and Versant Ventures. Audentes emphasizes strong relationships with patient, research, and medical communities and aims to be a global leader in gene therapy. Audentes Therapeutics is a biotechnology company focused on developing innovative treatments for rare muscle diseases using adeno-associated virus (AAV) gene therapy. Its two lead programs are AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease. The company says the financing will allow it to further advance those programs and evaluate additional candidate programs. Audentes was founded in November 2012 by Matthew R. Patterson in collaboration with Thomas J. Schuetz and OrbiMed Advisors and is headquartered in San Francisco. Matthew R. Patterson serves as President and CEO and the company emphasizes relationships with patient, research, and medical communities. The organization positions a focused team committed to advancing gene-therapy approaches for serious orphan muscle diseases.

Total raised

$138M

Funding rounds

3

Latest round

Series C

Latest activity

Oct 2015